Vyome Holdings, Inc. (formerly known as ReShape Lifesciences, Inc.) reported a significant decline in revenue for the first quarter of 2026, generating $31,591 compared to $198,581 in the same period of 2025. This represents a decrease of approximately 84%. The company's cost of goods sold also decreased to $14,946 from $44,162, leading to a gross profit of $16,645, down from $154,419 year-over-year. The operating loss widened to $1,129,940 from $198,998, contributing to a net loss of $985,521, compared to a net loss of $293,974 in the prior year.
The financial performance reflects the impact of the company's strategic shift following its merger with Vyome Therapeutics, which was completed on August 15, 2025. The merger resulted in a reorganization of the company's operations, focusing on biotechnology and the development of immuno-inflammatory treatments. Research and development expenses surged to $666,405 from $90,268, as the company intensified its efforts on clinical trials and regulatory preparations for its lead product, VT-1953, a topical gel for malignant fungating wounds.
Operationally, Vyome Holdings has made significant changes, including a reverse stock split of 1-for-4 and the issuance of new stock options under a revised equity incentive plan. The company also reported a cash balance of $8,795,783 as of March 31, 2026, a substantial increase from $4,982,333 at the end of 2025, primarily due to proceeds from an at-the-market (ATM) offering that generated $5,288,868. The company’s total assets rose to $10,185,446, up from $6,497,177, while total liabilities decreased to $2,144,125 from $2,735,160.
Looking ahead, Vyome Holdings anticipates continued operational losses as it invests in the development of its product candidates. The company is actively seeking additional funding through equity offerings and collaborations to support its growth strategy. Management has indicated that while they believe current cash reserves will sustain operations for at least the next 12 months, the need for further financing remains critical to advance clinical trials and other development activities. The company is also preparing for discussions with the FDA regarding pivotal trial protocols for its lead product in the upcoming quarters.
About ReShape Lifesciences Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.